FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/26/2022
Back to search
Official data from USPTO
ADRESTIA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ADRESTIA
ST13
US500000079307379Class
1, 5, 42, 44
Filing
79307379
Registration
6709002
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
09/26/2022
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
12/08/2020
Registration date
04/26/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/26/2022
Last transaction
04/26/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
MURRAY, GEORGE WILLIAM
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Adrestia Therapeutics Ltd
Representatives
BEN NATTER HAUG PARTNERS, LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in science; biological preparations for use in science; biochemicals for research use; cell lines and bio-production cell lines for scientificlaboratory or medical research; reagentsplasmids and assays for scientificgenetic and medical research; molecular biology research toolsin the nature of biological and biochemical reagents; biological and chemical reagents for research use; chemical reagents for scientific and research purposes; proteins in raw material form for scientific and medical research; gene extracts for research purposes; chemicals and biochemicals for drug discoverylead identificationdiagnosticsprofiling and research
Class 5
Medical and veterinary preparations for the treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases in humans and animals; pharmaceutical substances and preparations for human use for the diagnosis and treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases; biopharmaceutical substances and preparations for human use for use in the diagnosis and treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases; reagentsdiagnostic preparations and therapeutic preparations in the nature of biologicalbiochemical and chemical reagents and vaccines for medical purposes; biological preparations for medical purposesfor the diagnosis and treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases; medical preparations for use in gene therapy; diagnostic preparations for medical purposes; therapeutic and diagnostic preparationssmall molecules for medical use
Class 42
Medicalscientific and industrial research services in the field of cellscell therapiesgenome editinggenetic engineering and gene therapies and targeting therapies to individuals; pharmaceutical and biopharmaceutical research and development services; medical and pharmacological research services; examination and testing of genes for scientific research purposes; developmentexamination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; developmentexamination and testing of medicaments products; development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medicalpharmaceutical and biopharmaceutical field; development of gene databases; research and development services in the creation of databases and collections of information on biologicalsgenetic materialgenetic informationchemicals and compounds for research purposes; providing biological and medical research information; providing scientific research information and data in relation to health and disease state; medical research into personalised medicine; medical research services in the field of personalised diagnosticsmedical research services in the field of personal medical profiles; provision of scientific research information in the field of personalised medicine; pharmaceutical drug development services; consultancy and advisory relating to all the aforesaid services
Class 44
Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticalsnamely pharmaceutical compounding services for others; providing personalised medicine services and personalised medical diagnostic reporting services; providing personal medical information; provision of medical information; provision of information to enable human diagnosis of medical conditions; providing medical information to enable healthcare professionals to enable the monitoring of patients; providing medical information to healthcare professionals to enable the assessment of progress in disease and treatment; consultancy and advisory relating to all the aforesaid services
Publications
History of USPTO decisions and trademark events.
38 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/02/2022
FIMP
FINAL DISPOSITION PROCESSED
09/02/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/26/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
04/26/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/08/2022
PUBO
PUBLISHED FOR OPPOSITION
02/08/2022
GPNX
NOTIFICATION PROCESSED BY IB
02/06/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/20/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/20/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/19/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/19/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/19/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/03/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
12/23/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/23/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
12/23/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/23/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/22/2021
GNFR
FINAL REFUSAL E-MAILED
12/22/2021
CNFR
FINAL REFUSAL WRITTEN
12/22/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/14/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/14/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/14/2021
RFNT
REFUSAL PROCESSED BY IB
07/11/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/21/2021
RFRR
REFUSAL PROCESSED BY MPU
06/21/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/12/2021
CNRT
NON-FINAL ACTION WRITTEN
06/11/2021
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
06/07/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/29/2021
CNRT
NON-FINAL ACTION WRITTEN
05/28/2021
DOCK
ASSIGNED TO EXAMINER
05/28/2021
MAFR
APPLICATION FILING RECEIPT MAILED
03/30/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/26/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/25/2021
Continuous trademark protection
Get notified about every new filing that threatens ADRESTIA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.